- Previous Close
3,840.00 - Open
3,840.00 - Bid 3,830.00 x --
- Ask 3,840.00 x --
- Day's Range
3,820.00 - 3,840.00 - 52 Week Range
3,820.00 - 5,100.00 - Volume
10,000 - Avg. Volume
57,574 - Market Cap (intraday)
1.716T - Beta (5Y Monthly) 0.63
- PE Ratio (TTM)
12.80 - EPS (TTM)
299.14 - Earnings Date --
- Forward Dividend & Yield 320.00 (8.33%)
- Ex-Dividend Date Jun 7, 2024
- 1y Target Est
--
PT Merck Tbk engages in the manufacture and sale of pharmaceutical products in Indonesia and internationally. The company operates through three segments: Biopharma, Consumer Health, and Others. It offers health care products in the areas of cardiovascular, metabolic, oncology, endocrinology, fertility, and neurodegenerative diseases, as well as general medicines. The company also engages in research an, development, production, and distribution of pharmaceutical and biological prescription medicines to treat colorectal cancer, head and neck cancer, multiple sclerosis, infertility, growth hormone disorders, and diabetes, as well as thyroid disorders, such as hypothyroidism. In addition, it is involved in the office/property leasing and management activities. The company was formerly known as PT Merck Indonesia Tbk and changed its name to PT Merck Tbk in June 2002. The company was founded in 1970 and is headquartered in Jakarta Timur, Indonesia. PT Merck Tbk operates as a subsidiary of Merck Holding GmbH.
www.merckgroup.com/id-id377
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: MERK.JK
View MorePerformance Overview: MERK.JK
Trailing total returns as of 8/7/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MERK.JK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MERK.JK
View MoreValuation Measures
Market Cap
1.72T
Enterprise Value
1.66T
Trailing P/E
12.84
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.84
Price/Book (mrq)
2.46
Enterprise Value/Revenue
1.78
Enterprise Value/EBITDA
10.51
Financial Highlights
Profitability and Income Statement
Profit Margin
14.35%
Return on Assets (ttm)
9.36%
Return on Equity (ttm)
19.09%
Revenue (ttm)
934.43B
Net Income Avi to Common (ttm)
134.07B
Diluted EPS (ttm)
299.14
Balance Sheet and Cash Flow
Total Cash (mrq)
77.19B
Total Debt/Equity (mrq)
2.68%
Levered Free Cash Flow (ttm)
55.26B